What did SURMOUNT-3 do with participants who could not tolerate a step?

I have been on a stable schedule for eleven weeks, so this is not a first-week question.

I can parse the result. I am less sure what it licenses me to conclude.

I have deliberately not looked at anyone else’s interpretation yet.

What is the correct interpretation, and what is the common misreading?

SURMOUNT-3 would have written it into the protocol, and the wording is the part that matters. Escalation protocols in this class generally permit a delay at the current level, sometimes a single step down with a later re-attempt, and count a participant as remaining in the arm throughout. That is analytically important: an intention-to-treat analysis keeps them at their randomised assignment regardless of the dose they were actually taking, so the "top dose" arm contains people who never reached the top dose. Find the protocol amendment history as well as the paper, because tolerability rules are among the things most often revised mid-programme, and dose-escalation decisions are made under supervision — nothing here is medical advice.

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Weekly dosing accumulation, 7-day half-life

This is why a four-week step interval is approximately, but not exactly, steady state.

The part that matters: titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

Slower costs time and nothing else. The ceiling is the same.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

It helps to be literal here: the published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Hold rather than escalate while symptoms are active. Always.

It helps to be literal here: escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

The part that matters: liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

Stepping back is a normal adjustment, not a failure.

edited 20 Aug 2025 by Dr_Bram_Verhoeven — reworded for clarity after a comment

The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

The top of the schedule is not the target. The working dose is.

edited 20 Aug 2025 by Dr_Nadia_Farsi — added the method parameters